Whitepaper
13 May 2021

Catalent Oral Technology - Case Study Title: Expediting Path to Clinic with OptiForm® Total Supply

PDF 74 kB

MGB Biopharma (MGB), a biotech company based in Scotland, U.K., is developing a new class of anti-infective medicine based on Minor Groove Binder compounds. MGB-BP-3, a novel small molecule is currently in Phase 2a in the U.S. and Canada. The drug is being developed for the treatment of Clostridium difficile-associated diarrhea. The Catalent sites located in San Diego, CA and Kansas City, MO offered a tablet formulation as a solution to MGB’s needs ,in the form of OptiForm® Total Supply, allowing the integration of formulation development, clinical trial material (CTM) manufacturing, and supply and distribution to patients. Within five months, the first clinical trial kits were successfully delivered to MGB’s patients.

Content provided by our supplier

Catalent Pharma Solutions

  • US
  • 2015
    On CPhI since
  • 1
    Certificates
  • 5000+
    Employees

Other Content from Catalent Pharma Solutions